Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Helix BioPharma Corp.
HBPHelix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada. Address: 1055 West Georgia Street, Vancouver, BC, Canada, V6E 3P3
Analytics
Objectif de Cours de WallStreet
3.5 CADRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés HBP
Analyse des dividendes HBP
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes HBP
Valorisation des titres HBP
financières HBP
Résultats | 2019 | Dynamique |